Browse > Article

Efficacy Evaluation of Tissue Inhibitor of Metalloproteinases-2 and Endostatin on Angiogenesis  

Kim, Soo-Hyeon (Department of Molecular Bioscience, College of Biomedical Science, Kangwon National University)
Cho, Young-Rak (Department of Molecular Bioscience, College of Biomedical Science, Kangwon National University)
Yoon, Hyun-Jae (Department of Molecular Bioscience, College of Biomedical Science, Kangwon National University)
Ko, Hee-Young (Department of Molecular Bioscience, College of Biomedical Science, Kangwon National University)
Kim, Pyeung-Hyeun (Department of Molecular Bioscience, College of Biomedical Science, Kangwon National University)
Seo, Dong-Wan (Department of Molecular Bioscience, College of Biomedical Science, Kangwon National University)
Publication Information
YAKHAK HOEJI / v.54, no.6, 2010 , pp. 488-493 More about this Journal
Abstract
Therapeutic manipulation of angiogenesis, the formation of new vascular sprouts from existing capillaries, is one of the promising strategies for treatment of human diseases such as cancer, arthritis, and cardiovascular disorder. In the present study, we examined the effects and molecular mechanism of tissue inhibitor of metalloproteinases-2 (TIMP-2) and endostatin on fibroblast growth factor-2 (FGF-2)-stimulated endothelial cell proliferation, migration and adhesion in vitro, and angiogenesis in vivo. TIMP-2 and endostatin showed potent anti-angiogenic activity in vitro and in vivo. These effects appear to be mediated through different angiogenic signaling pathways. Collectively, our findings demonstrate that TIMP-2 and endostatin strongly inhibit FGF-2-induced angiogenic responses, and the establishment of fast and reproducible evaluation system in vitro and in vivo for the development of anti-angiogenic biomaterials and therapeutics.
Keywords
TIMP-2; endostatin; angiogenesis; efficacy evaluation;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Kerbel, R. and Folkman, J. : Clinical translation of angiogenesis inhibitors. Nat. Rev. Cancer 2, 727 (2002).   DOI   ScienceOn
2 Hoegy, S. E., Oh, H. R., Corcoran, M. L. and Stetler- Stevenson, W. G. : Tissue inhibitor of metalloproteinases-2 (TIMP-2) suppresses TKR-growth factor signaling independent of metalloproteinase inhibition. J. Biol. Chem. 276, 3203 (2001).   DOI   ScienceOn
3 Seo, D. W., Kim, S. H., Eom, S. H., Yoon, H. J., Cho, Y. R., Kim, P. H., Kim, Y. K., Han, J. W., Diaz, T., Wei, B. Y. and Stetler- Stevenson, W. G. : TIMP-2 disrupts FGF-2-induced downstream signaling pathways. Microvasc. Res. 76, 145 (2008).   DOI   ScienceOn
4 Oh, J., Seo, D. W., Diaz, T., Wei, B., Ward, Y., Ray, J. M., Morioka, Y., Shi, S., Kitayama, H., Takahashi, C., Noda, M. and Stetler-Stevenson, W. G. : Tissue inhibitors of metalloproteinase 2 inhibits endothelial cell migration through increased expression of RECK. Cancer Res. 64, 9062 (2004).   DOI   ScienceOn
5 Guedez, L., Rivera, A. M., Salloum, R., Miller, M. L., Diegmueller, J. J., Bungay, P. M. and Stetler-Stevenson, W. G. : Quantitative assessment of angiogenic responses by the directed in vivo angiogenesis assay. Am. J. Pathol. 162, 1431 (2003).   DOI   ScienceOn
6 Seo, D. W., Li, H., Qu, C. K., Oh, J., Kim, Y. S., Diaz, T., Wei, B. Y., Han, J. W. and Stetler-Stevenson, W. G. : Shp-1 mediates the anti-proliferative activity of tissue inhibitor of metalloproteinase-2 in human microvascular endothelial cells. J. Biol. Chem. 281, 3711 (2006).   DOI
7 Zhang, H. and Issekutz, A. C. : Down-modulation of monocyte transendothelial migration and endothelial adhesion molecule expression by fibroblast growth factor: reversal by the antiangiogenic agent SU6668. Am. J. Pathol. 160, 2219 (2002).   DOI   ScienceOn
8 Wingfield, P. T., Sax, J. K., Stahl, S. J., Kaufman, J., Palmer, I., Chung, V., Corcoran, M. L., Kleiner, D. E. and Stetler- Stevenson, W. G. : Biophysical and functional characterization of full-length, recombinant human tissue inhibitor of metalloproteinases-2 (TIMP-2) produced in Escherichia coli. Comparison of wild type and amino-terminal alanine appended variant with implications for the mechanism of TIMP functions. J. Biol. Chem. 274, 21362 (1999).   DOI
9 Murphy, A. N., Unsworth, E. J. and Stetler-Stevenson, W. G. : Tissue inhibitor of metalloproteinases-s inhibits bFGF-induced human microvascular endothelial cell proliferation. J. Cell. Physiol. 157, 351 (1993).   DOI   ScienceOn
10 Chang, Z., Choon, A. and Friedl, A. : Endostatin binds to blood vessels in situ independent of heparan sulfate and does not compete for fibroblast growth factor-2 binding. Am. J. Pathol. 155, 71 (1999).   DOI   ScienceOn
11 Schwartz, M. A. : Integrin signaling revisited. Trends Cell Biol. 11, 466 (2001).   DOI   ScienceOn
12 Hynes, R. O. : Integrins: bidirectional, allosteric signaling machines. Cell 110, 673 (2002).   DOI   ScienceOn
13 Nyberg, P., Xie, L. and Kalluri, R. : Endogenous inhibitors of angiogenesis. Cancer Res. 65, 3967 (2005).   DOI   ScienceOn
14 Dixelius, J., Cross, M., Matsumoto, T., Sasaki, T., Timpl, R. and Claesson-Welsh, L. : Endostatin regulates endothelial cell adhesion and cytoskeletal organization. Cancer Res. 62, 1944 (2002).
15 Marneros, A. G. and Olsen, B. R. : Physiological role of collagen XVIII and endostatin. FASEB J. 19, 716 (2005).   DOI   ScienceOn
16 Lee, S. J., Jang, J. W., Kim, Y. M., Lee, H. I., Jeon, J. Y., Kwon, Y. G. and Lee, S. T. : Endostatin binds to the catalytic domain of matrix metalloproteinase-2. FEBS Lett. 519, 147 (2002).   DOI   ScienceOn
17 Wickstrom, S. A., Alitalo, K. and Keski-Oja, J. : An endostatin-derived peptide interacts with integrins and regulates actin cytoskeleton and migration of endothelial cells. J. Biol. Chem. 279, 20178 (2004).   DOI   ScienceOn
18 Kim, Y. M., Hwang, S., Kim, Y. M., Pyun, B. J., Kim, T. Y., Lee, S. T., Gho, Y. S. and Kwon, Y. G. : Endostatin blocks vascular endothelial growth factor-mediated signaling via direct interaction with KDR/Flk-1. J. Biol. Chem. 277, 27872 (2002).   DOI   ScienceOn
19 Folkman, J. : Antiangiogenesis in cancer therapy-endostatin and its mechanisms of action. Exp. Cell Res. 312, 594 (2006).   DOI   ScienceOn
20 Carmeliet, P. : Mechanisms of angiogenesis and arteriogenesis. Nat. Med. 6, 389 (2000).   DOI   ScienceOn
21 Carmeliet, P. and Jain, R. K. : Angiogenesis in cancer and other diseases. Nature 407, 249 (2000).   DOI   ScienceOn
22 Blagosklonny, M. V. : Antiangiogenic therapy and tumor progression. Cancer. Cell. 5, 13 (2004).   DOI   ScienceOn
23 Sternlicht, M. D. and Werb, Z. : How matrix metalloproteinases regulate cell behavior. Annu. Rev. Cell. Dev. Biol. 17, 463 (2001).   DOI   ScienceOn
24 Stetler-Stevenson, W. G. : Tissue inhibitors of metalloproteinases in cell signaling: metalloproteinase-independent biological activities. Sci. Signal. 1, re6 (2008).   DOI   ScienceOn
25 Stetler-Stevenson, W. G. : Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention. J. Clin. Invest. 103, 1237 (1999).   DOI   ScienceOn
26 Baker, A. H., Edwards, D. R. and Murphy, G. : Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J. Cell Sci. 115, 3719 (2002).   DOI   ScienceOn
27 Seo, D. W., Li, H., Guedez, L., Wingfield, P. T., Diaz, T., Salloum, R., Wei, B. Y. and Stetler-Stevenson, W. G. : TIMP-2 mediated inhibition of angiogenesis : an MMP-independent mechanism. Cell. 114, 171 (2003).   DOI   ScienceOn